<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154554">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01688791</url>
  </required_header>
  <id_info>
    <org_study_id>8109-001</org_study_id>
    <secondary_id>2012-002799-14</secondary_id>
    <nct_id>NCT01688791</nct_id>
  </id_info>
  <brief_title>A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)</brief_title>
  <official_title>A Phase I Dose Escalation Study Evaluating Vintafolide (MK-8109) Chemotherapy Alone or in Combination in Adult Subjects With Advanced Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will be conducted in three parts. Part A is a dose escalation trial followed by a
      dose confirmation trial in folate receptor (FR) 100% endometrial cancer participants. The
      primary hypothesis of this trial is that administration of vintafolide in combination with
      carboplatin and paclitaxel is safe and tolerable. Part B is a single dose, dose escalation,
      pharmacokinetic (PK), and QTc interval trial. The primary objectives include determination
      of the maximum single tolerated dose of vintafolide and to evaluate the effect of this
      single maximum dose on the QTc interval. Part C is a weekly dose escalation trial of
      vintafolide followed by a dose confirmation. The primary hypothesis of this part is that
      weekly vintafolide has acceptable safety and tolerability in participants with advanced
      cancers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Parts A and C: Number of participants with dose-limiting toxicities (DLTs)</measure>
    <time_frame>Cycle 1 (21 days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change from Baseline in QTc interval</measure>
    <time_frame>30 minutes pre-dose and up to 2 hours post-dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C: Number of Participants Experiencing an Adverse Event (AE)</measure>
    <time_frame>Up to 18 weeks (six 3-week cycles)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants whose best response is partial response (PR) or complete response (CR)</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Pharmacokinetics (PK) of vintafolide, including Area Under the Curve (AUC) and Maximum Concentration (Cmax)</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: PK of Vintafolide Metabolites, including AUC and Cmax</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Part A: Vintafolide BIW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vintafolide, intravenously (IV), on Days 1, 4, 8, and 11 of each 21-day cycle. Carboplatin, IV, at a dose of area under the curve (AUC)5, administered on Day 1 of each 21-day cycle. Paclitaxel, IV, at a dose of 175 mg/m^2, administered on Day 1 of each 21-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Vintafolide TIW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vintafolide, intravenously (IV) on Days 1, 3, 5, 8, 10, and 12 of each 21-day cycle. Carboplatin, IV, at a dose of area under the curve (AUC)5, administered on Day 1 of each 21-day cycle. Paclitaxel, IV, at a dose of 175 mg/m^2, administered on Day 1 of each 21-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parts B &amp; C: Vintafolide Single Dose &amp; Weekly (QW)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, dose escalation, vintafolide (Part B) followed by 2 week observation. Those completing Part B will have the option to continue on to Part C (weekly dosing, dose finding, on Days 1, 8, and 15 in a 21-day cycle until disease progression or toxicity) unless they experience severe and/or persistent drug related toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vintafolide</intervention_name>
    <arm_group_label>Part A: Vintafolide BIW</arm_group_label>
    <arm_group_label>Part A: Vintafolide TIW</arm_group_label>
    <arm_group_label>Parts B &amp; C: Vintafolide Single Dose &amp; Weekly (QW)</arm_group_label>
    <other_name>MK-8109</other_name>
    <other_name>EC-145</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Part A: Vintafolide BIW</arm_group_label>
    <arm_group_label>Part A: Vintafolide TIW</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Part A: Vintafolide BIW</arm_group_label>
    <arm_group_label>Part A: Vintafolide TIW</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for all participants:

          -  Histologically-confirmed metastatic or locally advanced solid tumor that has failed
             to respond to standard therapy, progressed despite standard therapy, or for which
             standard therapy does not exist or is unacceptable to the participant

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  At least one measurable metastatic or recurrent lesion

          -  No history of a previous malignancy with the exception of cervical intraepithelial
             neoplasia, basal cell carcinoma of the skin, or adequately treated localized prostate
             carcinoma; or has undergone potentially curative therapy with no evidence of disease
             for five years

          -  Adequate organ function

          -  Female participants of childbearing potential must be willing to use acceptable
             methods of birth control or abstain from heterosexual activity for the course of the
             study through 90 days after the last dose of study therapy

          -  Male participants must agree to use an adequate method of contraception for
             heterosexual activity starting with the first dose of study therapy through 90 days
             after the last dose of study therapy

        Inclusion criteria for Part A:

          -  Tumor lesions characterized as folate receptor (FR) 100% as determined by an
             etarfolide Sequential Single Photon Emission Computed Tomography (SPECT) and CT scan

          -  Histologically-confirmed diagnosis of locally advanced or metastatic or recurrent
             endometrial cancer

        Inclusion criteria for Parts B &amp; C:

        - Must have an etarfolatide SPECT/CT scan to determine FR status

        Exclusion criteria for all participants:

          -  Part A &amp; Part C if enrolled after completion of Part B:  Chemotherapy, radiotherapy,
             or biological therapy (including monoclonal antibodies) within 4 weeks prior to drug
             administration, or not recovered from adverse events due to agents administered more
             than 4 weeks earlier

          -  Part B:  Chemotherapy, radiotherapy, or biological therapy (including monoclonal
             antibodies) within 3 weeks prior to drug administration, or not recovered from
             adverse events due to agents administered more than 4 weeks earlier

          -  Currently participating or has participated in a study with an investigational
             compound  or device within 28 days of initial dosing on this study

          -  Part A, dose escalation, Parts B and C: More than 3 prior cytotoxic regimens for
             metastatic disease.

          -  Part A, dose confirmation: Has received more than 2 prior cytotoxic regimens for
             metastatic disease.

          -  Primary central nervous system (CNS) tumor

          -  Active CNS metastases and/or carcinomatous meningitis.

          -  Known hypersensitivity to the components of the study therapy or its analogs

          -  Recent (i.e., â‰¤ 6 weeks) history of abdominal surgery or peritonitis

          -  Bowel occlusion or sub-occlusion

          -  Prior whole abdominal or whole pelvis radiation therapy or radiation therapy to &gt;10%
             of the bone marrow at any time in the past or prior radiation therapy within the last
             3 years to the breast / sternum, head, or neck

          -  Requires anti-folate therapy for the management of co-morbid conditions

          -  Known regular user (including &quot;recreational use&quot;) of any illicit drugs or had a
             recent history (within the last year) of drug or alcohol abuse

          -  Pregnant or breastfeeding or expecting to conceive, or donate sperm within the span
             of the study

          -  Human Immunodeficiency Virus (HIV)-positive

          -  Active Hepatitis B or C

          -  Symptomatic ascites or pleural effusion.

          -  History of stem cell or bone marrow transplant

        Exclusion Criteria for Part B:

          -  Permanent pacemaker

          -  Unable to refrain from use of all concomitant medications on Day 1

          -  Structural heart disease, history of myocardial infarction (MI), or unstable angina

          -  History of cardiac arrhythmia, congestive heart failure (CHF), sick sinus syndrome,
             second or third degree atrioventricular (AV) block

          -  History of risk factors for Torsades de Pointes such as CHF, uncorrected hypokalemia,
             family history of long QT syndrome
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0001)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MSD France</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Blazy</last_name>
      <phone>33 147548990</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Co. Ltd.</name>
      <address>
        <city>Hod Hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ofer Sharon</last_name>
      <phone>972 9 9539310</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>France</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>September 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinca Alkaloids</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
